PURPOSE: Chronic kidney disease (CKD) is a prevalent and important outcome and covariate in pharmacoepidemiology. The Health Improvement Network (THIN) in the UK represents a unique resource for population-based studies of CKD. We compiled a valid list of Read codes to identify subjects with moderate to advanced CKD. METHODS: A cross-sectional validation study was performed to identify codes that best define CKD Stages 3-5. All subjects with at least one non-zero measure of serum creatinine after 1 January 2002 were included. Estimated glomerular filtration rate (eGFR) was calculated according to the Schwartz formula for subjects aged < 18 years and the Modification of Diet in Renal Disease formula for subjects aged ≥ 18 years. CKD was defined as an eGFR <60 mL/minute/1.73 m² on at least two occasions, more than 90 days apart. RESULTS: The laboratory definition identified 230,426 subjects with CKD, for a period prevalence in 2008 of 4.56% (95%CI, 4.54-4.58). A list of 45 Read codes was compiled, which yielded a positive predictive value of 88.9% (95%CI, 88.7-89.1), sensitivity of 48.8%, negative predictive value of 86.5%, and specificity of 98.2%. Of the 11.1% of subjects with a code who did not meet the laboratory definition, 83.6% had at least one eGFR <60. The most commonly used code was for CKD Stage 3. CONCLUSIONS: The proposed list of codes can be used to accurately identify CKD when serum creatinine data are limited. The most sensitive approach for the detection of CKD is to use this list to supplement creatinine measures.
PURPOSE:Chronic kidney disease (CKD) is a prevalent and important outcome and covariate in pharmacoepidemiology. The Health Improvement Network (THIN) in the UK represents a unique resource for population-based studies of CKD. We compiled a valid list of Read codes to identify subjects with moderate to advanced CKD. METHODS: A cross-sectional validation study was performed to identify codes that best define CKD Stages 3-5. All subjects with at least one non-zero measure of serum creatinine after 1 January 2002 were included. Estimated glomerular filtration rate (eGFR) was calculated according to the Schwartz formula for subjects aged < 18 years and the Modification of Diet in Renal Disease formula for subjects aged ≥ 18 years. CKD was defined as an eGFR <60 mL/minute/1.73 m² on at least two occasions, more than 90 days apart. RESULTS: The laboratory definition identified 230,426 subjects with CKD, for a period prevalence in 2008 of 4.56% (95%CI, 4.54-4.58). A list of 45 Read codes was compiled, which yielded a positive predictive value of 88.9% (95%CI, 88.7-89.1), sensitivity of 48.8%, negative predictive value of 86.5%, and specificity of 98.2%. Of the 11.1% of subjects with a code who did not meet the laboratory definition, 83.6% had at least one eGFR <60. The most commonly used code was for CKD Stage 3. CONCLUSIONS: The proposed list of codes can be used to accurately identify CKD when serum creatinine data are limited. The most sensitive approach for the detection of CKD is to use this list to supplement creatinine measures.
Authors: Simon de Lusignan; Tom Chan; Paul Stevens; Donal O'Donoghue; Nigel Hague; Billy Dzregah; Jeremy Van Vlymen; Mel Walker; Sean Hilton Journal: Fam Pract Date: 2005-04-06 Impact factor: 2.267
Authors: Ronac Mamtani; Kevin Haynes; Warren B Bilker; David J Vaughn; Brian L Strom; Karen Glanz; James D Lewis Journal: J Natl Cancer Inst Date: 2012-08-09 Impact factor: 13.506
Authors: Ravy K Vajravelu; Lawrence Copelovitch; Mark T Osterman; Frank I Scott; Ronac Mamtani; James D Lewis; Michelle R Denburg Journal: Clin Gastroenterol Hepatol Date: 2019-11-01 Impact factor: 11.382
Authors: D E Freedberg; K Haynes; M R Denburg; B S Zemel; M B Leonard; J A Abrams; Y-X Yang Journal: Osteoporos Int Date: 2015-05-19 Impact factor: 4.507
Authors: Claire E Lefebvre; Kristian B Filion; Pauline Reynier; Robert W Platt; Michael Zappitelli Journal: Clin J Am Soc Nephrol Date: 2019-12-12 Impact factor: 8.237
Authors: Ronac Mamtani; Kevin Haynes; Brian S Finkelman; Frank I Scott; James D Lewis Journal: Pharmacoepidemiol Drug Saf Date: 2013-12-19 Impact factor: 2.890